agents on-board should be vigorously monitored and opioid dosing constrained. 6 Pre-existing headache, back pain, mental health, and substance use disorders were significantly associated with both additional ED and alcohol-or drug-related encounters (ADEs) . The use of schedule II long-acting opioids was strongly associated with ADEs and strong cautions against such practices seem warranted. 7 It has been well documented that we are using opioids to effectively reduce patient suffering, in many differing clinical conditions. [8] [9] [10] Time to effective analgesia is especially important for those with severe pain from whatever source. Efforts to reduce unnecessary administration and use of opioids are appropriate, but they should not constrain our ability to provide necessary relief. This includes short-term ED prescriptions for analgesics, where no clear contribution to subsequent abuse can be shown. 11, 12 However, given the recent association between opioid prescription and subsequent recurrent use, we should exercise appropriate cautions and use non-opioids when possible. 13 Increasingly states have adopted approaches to monitor and provide practitioner feedback opportunities to monitor prescription drug prescribing. Reducing over-consumption, diversion and other misuses of prescription medications is an important goal shared by emergency medicine practitioners. 14 Providing for life-saving and innovative interventions in the ED and our communities should be strongly considered. Mechanisms and policy for advancing the use of community based reversal of opioid over-doses is lifesaving. 15 The administration of agents (like buprenorphine/ naloxone) beginning during ED based care, has recently been shown to be beneficial compared to other strategies for opioid addicted patients. 16 So it seems we have effective analgesic agents with a good safety margin when used appropriately with safe monitoring. Our ability to utilize them appropriately appears to depend upon early administration, dosage adjustment for patients at risk of adverse effects, appropriate monitoring, and advocating for innovations which will assist in reducing the risk of substance abuse and treatments.
